

e-Newsletter

Issue 13 · October 2008

Top stories of this issue

- Kunming Jida Is Awarded the Title of a 100 Outstanding and Strong Enterprise
- Edaravone injections and bulk materials are granted registration approval
- The Bioequivalence Test of Fluconazole Capsules and Azithromycin Dispersible Tablets have been Successfully Completed
- Citalopram bulk materials obtain GMP certification



Corporate News

Mr. Chiu Wai Piu Appointed Independent Non-Executive Director

On September 1st, 2008, the company's board of directors announced Mr. Chiu Wai Piu as Independent Non-Executive Director, Chairman of the Nominating Committee, and member of the Audit Committee and the Remuneration Committee.

Mr. Chiu Wai Piu is a senior journalist and is currently Assistant Chief Editor of Wen Wei Po. He has over 40 years' experience in journalism. He has worked as a reporter, editor, top news editor, local news editor, assistant chief editor, author of editorials, and as the senior research officer of the One Country Two Systems Research Institute (OCTSRI). He has served as the founding treasurer and the second chairman of the Hong Kong Federation of Journalists. In 2008,

he was elected Vice Secretary-General and Treasurer when new committee members were elected for the Hong Kong Federation of Journalists. For many years Mr. Chiu has been devoting himself to boost cooperation among local journalists, enhance the professional conduct of journalists, and develop good relationships and communication between journalists in Hong Kong and mainland China.


Mr. Chiu joining the company's board of directors will help Jiwa Group enhance communication between the media and investors, and improve the quality of management. 



Annual General Meeting 2008



On August 26th, 2008, the group held the Annual General Meeting 2008. The attending shareholders recognised the performance submitted by the company and the work of the management. During the meeting, the management gave detailed explanations to shareholders' inquiries on business. After the meeting, the Group's Vice Chairman and CEO Mr. Lau Kin Tung met with the media, and announced that all four products the Group has developed by itself, including Citalopram tablets for anti-depression and psychiatric disorders, Sucralfate Gel Suspension for the digestive system, Risedronate Sodium tablets for muscles and bones, and Edaravone injections for cardiovascular and cerebrovascular diseases, have successfully acquired national approval and will be put on the market in either 2008 or 2009.

"For the four new drugs acquiring approval from the State Food and Drug Administration, the Group has coordinated its work in various aspects, including launching production workshops and starting marketing campaigns. These products are expected to enter the market between 2008 and 2009. As the materials for the four products are produced by Jiwa itself, it is estimated that the gross profit margin may be as high as 80%. The management is confident that they can provide a good return to the Group after the market introduction stage." Mr. Lau said in the meeting. 






Kunming Jida Is Awarded the Title of a 100 Outstanding and Strong Enterprise

On the morning of July 31st, 2008, the Yunnan Provincial Party Committee and Provincial Government held the Further Accelerating the Provincial Industrialisation Meeting. Attendants included leaders of the Provincial Party Committee, the Standing Committee of the Provincial People's Congress, the Provincial Government, and the Provincial Political Consultative Conference, major leaders of state and city party committees, and governments and principals of relevant functional departments, as well as major principles of relevant departments, committees, offices and bureaus of the provincial party committee and provincial government organs, relevant people's organizations, some province-owned enterprises and institutions, and relevant central units in Yunnan. At the meeting, the Provincial Government awarded the Top 10 Industrial Counties, 10 Outstanding Industrial Parks and Zones, 100 Outstanding and Strong Enterprises and 100 Outstanding Industrial Entrepreneurs.

In accordance with the Provincial Government's requirements, the selection of the above awards was led by the Provincial Economic Commission, and a number of evaluation procedures were taken following the selection method before the final lists appeared. In order to guarantee the fairness and transparency of the selection and awards, the lists were put under public review for one week.

After selections by various levels of governmental departments, Kunming Jida was listed as a 100 Outstanding and Strong Enterprise. It is a return to the Company for its years of hard work, and is also a mission and a driving force for it to continue to work hard in the future. 

Market Digest & Product News


Edaravone injections and bulk materials are granted registration approval

In August 2008, the Group's new Category II drug Edaravone injections and bulk materials were granted registration approval, which was the fourth new product approval granted to the Group following Risedronate Sodium, Citalopram Hydrobromide and Sucralfate Gel Suspension.

Edaravone is a neuroprotective agent (radical scavenging agent) used to ease nerve symptoms caused by acute cerebral infarction, and to treat motor dysfunction during daily activities. It is completely different to traditional drugs. It does not influence the functions of the coagulation or fibrinolytic system of patients. It treats various diseases and is especially effective for cerebral infarction patients with bleeding tendencies. Its mechanism of action is that by scavenging radicals of the lesion, it interrupts the process of brain cell injury and minimises the number of injured brain cells to maintain patients' normal functioning to the maximum, and prevent the condition from getting any worse. Edaravone is a powerful radical scavenging agent and inhibits the

forming of radicals and lipid peroxides to protect brain tissue, ease symptoms of cranial nerve injury and help the recovery of nervous functions.

In 2006, the Company officially applied to the Yunnan competent authority for production of this product. After two years of strict technical evaluation and national pharmaceutical registration examination, especially the aseptic processing verification and research according to the latest national technical requirements, satisfactory results have been achieved and Edaravone Injections and bulk materials have successfully been granted pharmaceutical registration approval.

Edaravone Injection is a Category II drug. There are only two brands of this type of drug in China. After the market introduction stage, this product is estimated to occupy 25-30% of the Chinese market share. 

The Bioequivalence Test of Fluconazole Capsules and Azithromycin Dispersible Tablets have been Successfully Completed

After more than six months of effort, with unstable pharmaceutical policies and increasingly more standard and stricter clinical trial requirements, the bioequivalence test of Fluconazole Capsules and Azithromycin Dispersible Tables developed by the Medical Department of the Group has been successfully completed.

Both Fluconazole Capsules and Azithromycin Dispersible Tables are Category VI drugs. In accordance with the requirements set forth in the Measures for the Administration of Drug Registration, these two drugs only need to complete a bioequivalence test before applying for production.

Fluconazole is a new triazole antifungal agent and is clinically used for vaginal candidiasis, oral thrush, atrophic oral candidiasis, fungal meningitis, pulmonary fungal infection, abdominal infection, urinary tract infection and skin fungal infections.

Azithromycin is clinically used for serious infection caused by candidiasis, cryptococcosism and coccidioidomycosis.

To date, the clinical research before the application for production of fluconazole capsules and azithromycin dispersible tablets has been completed. The next step will be application for production, soon to enrich the company's product system.

Citalopram bulk materials obtain GMP certification

In September 2008, Citalopram produced by Jiangsu Jiwa Rintech officially obtained GMP certification. This not only marks that the company's production and quality management level has reached the standard of the State Food and Drug Administration, but also facilitates the development of the Chinese market and semi-regulated overseas markets for Citalopram. In just a short space of time as two weeks, the company has established Citalopram bulk drug supply agreements with several large Chinese pharmaceutical companies. Meanwhile, many semi-regulated market agents have started the registration process for exporting Citalopram with their national drug administrations.

Citalopram's obtaining GMP certification will drastically increase the company's sales avenue in 2009 and enhance the company's awareness and reputation. It will lay a solid foundation for the upcoming FDA certification and will be a landmark for the development of the group.



Sidelights of Corporate Activities

The Fifteenth National Urology Academic Conference


From 18th to 21st of September, 2008, the Fifteenth National Urology Academic Conference sponsored by the Chinese Urological Association and organised by the Yunnan Urological Association was held, and successfully finished at the Kunming International Convention and Exhibition Centre.

Kunming Jida took this conference as an opportunity to display the group's key product - Tamsulosin Hydrochloride Sustained Release Tablets (Jida Bente). The customised exhibition stand attracted a lot of attention: the introduction to the company shows the strength, the introduction by way of games shows the quality, and the introduction to games shows the



charm. The against-the-clock Klotski competition, combining the features of Jida Bente, made the attendants want to have a try, and the winners were very satisfied with the awards the company provided, such as Yunnan handcrafts. During the conference, attendants visited in an endless stream to view the company's exhibition stand and participate in the game.



The successful convening of the National Urology Academic Conference began a new chapter for the development of Chinese urology. The appearance of Jida Bente and Klotki in Kunming showed the new look of Jida Pharmaceuticals. The exhibition greatly increased the awareness of Jida Bente, and the marketing department estimates that the sales of this product will increase steadily next year, bringing considerable profits to the group. 

Disclaimer

Data and information contained in this e-Newsletter is provided for private circulation and informational purposes only and is for distribution only under such circumstances and to such recipients in such jurisdictions as may be permitted by applicable laws. This e-Newsletter is not intended to offer or solicit purchase or sale of shares in Jiwa Bio-Pharm Holdings Limited in any jurisdiction. Whilst reasonable effort has been made to ensure the information contained herein is not untrue or misleading at the time of circulation, the information contained herein may be changed. Use of any information herein shall be at the sole risk of the user. Jiwa Bio-Pharm Holdings Limited made no representation as to the accuracy and completeness of and expressly disclaimed any liability whatsoever for any loss howsoever arising from the information contained in this e-Newsletter.

This e-Newsletter may contain forward-looking statements that are based on the current beliefs, assumptions, expectations, estimates, and projections of the management of Jiwa Bio-Pharm Holdings Limited about its business and the industry and markets in which it operates. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, including but not limited to price fluctuations, actual demand, exchange rate fluctuations, development outcomes, market shares, competition, environmental risks, changes in legal, financial and regulatory frameworks, international economic and financial market conditions, political risks, project delay, project approval, cost estimates and other risks, which are beyond the control of Jiwa Bio-Pharm Holdings Limited and are difficult to predict. Consequently, actual results could differ materially from those expressed or forecasted in the forward-looking statements.

Editorial

Chief Editor: Lau Kin Tung (Vice Chairman and CEO of the Group)

Executive Editor: Carol Yue

Editorial Board: Kelvin Chu, Feng Pu Chun, Ma Ze Wen, Yang Min, Yu Qi, Wang Chang Wen

Enquiries: carol-finc-hk@jiwa.com.hk

Website: www.jiwa.com.hk